Search Results - "Oosterom, A."

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours by Sternberg, C.N., de Mulder, P., Schornagel, J.H., Theodore, C., Fossa, S.D., van Oosterom, A.T., Witjes, J.A., Spina, M., van Groeningen, C.J., Duclos, B., Roberts, J.T., de Balincourt, C., Collette, L.

“…EORTC protocol 30924 is an international randomized trial reporting a 7.3 year update of a 2 weekly regimen of high-dose intensity chemotherapy with M-VAC plus…”
Get full text

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group by Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., Scurr, M., Hagemeijer, A., Van Glabbeke, M., van Oosterom, A.T.

“…Previous studies have shown that activating mutations of c-KIT/ PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the…”
Get full text

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 by WILDIERS, H, GUETENS, G, DE BOECK, G, VERBEKEN, E, LANDUYT, B, LANDUYT, W, DE BRUIJN, E. A, VAN OOSTEROM, A. T

“…Promising preclinical activity with agents blocking the function of vascular endothelial growth factor (VEGF) has been observed in various cancer types,…”
Get full text

Prevalence of methicillin-resistant Staphylococcus aureus in meat by de Boer, E., Zwartkruis-Nahuis, J.T.M., Wit, B., Huijsdens, X.W., de Neeling, A.J., Bosch, T., van Oosterom, R.A.A., Vila, A., Heuvelink, A.E.

“…Recently the isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from several food-producing animals has been reported. During slaughtering…”
Get full text

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial by LE CESNE, A, BLAY, J. Y, COLLIN, F, JIMENO, J, DI PAOLA, E, VAN GLABBEKE, M, NIELSEN, O. S, JUDSON, I, VAN OOSTEROM, A, VERWEIJ, J, RADFORD, J, LORIGAN, P, RODENHUIS, S, RAY-COQUARD, I, BONVALOT, S

“…This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m(2)…”
Get full text

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924 by STERNBERG, C. N, DE MULDER, P. H. M, COLLETTE, L, SCHORNAGEL, J. H, THEODORE, C, FOSSA, S. D, VAN OOSTEROM, A. T, WITJES, F, SPINA, M, VAN GROENINGEN, C. J, DE BALINCOURT, C

“…This randomized trial evaluated antitumor activity of and survival asociated with high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin,…”
Get full text

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study by Verweij, J, van Oosterom, A, Blay, J.-Y, Judson, I, Rodenhuis, S, van der Graaf, W, Radford, J, Le Cesne, A, Hogendoorn, P.C.W, di Paola, E.D, Brown, M, Nielsen, O.S

“…The aim of this study was to assess the antitumour response and time to progression (TTP) of patients treated with imatinib mesylate (Glivec®, Gleevec™,…”
Get full text

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study by VAN GLABBEKE, M, VAN OOSTEROM, A. T, OOSTERHUIS, J. W, MOURIDSEN, H, CROWTHER, D, SOMERS, R, VERWEIJ, J, SANTORO, A, BUESA, J, TURSZ, T

“…A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven clinical trials investigating the use of doxorubicin- or…”
Get full text

A phase II trial with rosiglitazone in liposarcoma patients by DEBROCK, G, VANHENTENRIJK, V, SCIOT, R, DEBIEC-RYCHTER, M, OYEN, R, VAN OOSTEROM, A

“…Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte…”
Get full text

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group by Judson, I, Radford, J.A, Harris, M, Blay, J.-Y, van Hoesel, Q, le Cesne, A, van Oosterom, A.T, Clemons, M.J, Kamby, C, Hermans, C, Whittaker, J, Donato di Paola, E, Verweij, J, Nielsen, S

“…CAELYX®/DOXIL®, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types…”
Get full text

ECGSIM: an interactive tool for studying the genesis of QRST waveforms by van Oosterom, A, Oostendorp, T F

“…Background: Discussion about the selection of diagnostic features of the ECG and their possible interpretation would benefit from a model of the genesis of…”
Get full text

Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall by Pauwels, P, Debiec-Rychter, M, Stul, M, De Wever, I, Van Oosterom, A T, Sciot, R

“…Aims : The diagnosis of gastrointesinal stromal tumours (GISTs) is widely based on morphological features and KIT (CD117) immunoreactivity. Most patients with…”
Get full text

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy by Blay, J-Y, van Glabbeke, M, Verweij, J, van Oosterom, A.T, Le Cesne, A, Oosterhuis, J.W, Judson, I, Nielsen, O.S

“…Adult patients with metastatic or locally advanced irresectable soft-tissue sarcoma (ASTS) are generally considered as incurable. Whether some of these…”
Get full text

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours by Eskens, F.A.L.M, Dumez, H, Hoekstra, R, Perschl, A, Brindley, C, Böttcher, S, Wynendaele, W, Drevs, J, Verweij, J, van Oosterom, A.T

“…A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins αvβ3 and αvβ5, was performed to determine its…”
Get full text

Youth and social navigation in Zimbabwe’s informal economy: ‘Don’t end up on the wrong side by Oosterom, Marjoke A

“…This article draws on qualitative case study research in Murewa, a rural district town in Zimbabwe, to extend the use of the concept of ‘social navigation’…”
Get full text

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients by DIRLX, L. Y, VERMEUEEN, P. B, PAWINSKI, A, PROVE, A, BENOY, I, DE POOTER, C, MARTIN, M, VAN OOSTEROM, A. T

“…The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) was determined in the serum of 90 untreated and 42…”
Get full text

The effect of tissue geometry on the activation recovery interval of atrial myocytes by van Oosterom, A., Jacquemet, V.

“…The propagation of electric activity inside a realistically-shaped, thick-walled model of the atria was studied. The membrane kinetics was based on the…”
Get full text

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours by de Jonge, M.J.A., Dumez, H., Verweij, J., Yarkoni, S., Snyder, D., Lacombe, D., Marréaud, S., Yamaguchi, T., Punt, C.J.A., van Oosterom, A.

“…Halofuginone (tempostatin™) is a synthetic derivative of a quinazolinone alkaloid showing anti-angiogenic, anti-metastatic and anti-proliferative effects in…”
Get full text

Geometrical aspects of the interindividual variability of multilead ECG recordings by Hoekema, R., Uijen, G.J.H., van Oosterom, A.

“…The ECG as measured from healthy subjects shows a considerable interindividual variability. This variability is caused by geometrical as well as by…”
Get full text

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients by van Oosterom, A.T, Mouridsen, H.T, Nielsen, O.S, Dombernowsky, P, Krzemieniecki, K, Judson, I, Svancarova, L, Spooner, D, Hermans, C, Van Glabbeke, M, Verweij, J

“…The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as…”
Get full text